OAM
AXSM icon

Oxford Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Oxford Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-73,713
Closed -$208K – 1658
2018
Q4 		$208K Buy
+73,713
New +$243K 0.01% 1523

Other funds holding AXSM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Oxford Asset Management's AXSM Position: Q1 2019 in Review

Oxford Asset Management sold out of Axsome Therapeutics (AXSM) in Q1 2019, closing a stake of 73,713 shares — an estimated $208K sold.

Oxford Asset Management first reported a position in AXSM in Q4 2018 and held it in 1 quarter. The position peaked at $208K in Q4 2018. 65 funds tracked by Wall St. Rank hold AXSM as of Q1 2019.

  • Oxford Asset Management reported no remaining Axsome Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 73,713 Axsome Therapeutics shares in Q1 2019, an estimated $208K.
  • Oxford Asset Management first reported a position in Axsome Therapeutics in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Axsome Therapeutics position peaked at $208K in Q4 2018.
  • 65 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.